Search

Displaying results 3051 - 3060 of 8412 in total
  1. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. … Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions.

    Synonyms: d-PropoxypheneCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  2. Drug

    Perfluorohexyloctane

    go.drugbank.com/drugs/DB17823
    ApprovedInvestigational

    [L46491] It is an inert, slightly amphiphilic compound. … [A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative.

  3. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan. Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that...

  4. Drug

    Zansecimab

    go.drugbank.com/drugs/DB16389
    Investigational

    Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).

  5. Drug

    Ensitrelvir

    go.drugbank.com/drugs/DB18834
    ApprovedInvestigational

    Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  6. Drug

    Tetrachlorodecaoxide

    go.drugbank.com/drugs/DB05389
    Approved

    The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer.

  7. Drug

    ACR-16

    go.drugbank.com/drugs/DB05371
    Investigational

    ACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within ...

  8. Drug

    Trypan blue free acid

    go.drugbank.com/drugs/DB09158
    Approved

    Trypan blue is a diazo dye used in ophthalmic cataract surgery to stain the anterior capsule in the presence of a mature cataract. This is done to aid in visualization before creating the continuous curvilinear capsulorhexis.

  9. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

  10. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    Insulin icodec is an ultra long-acting basal insulin analogue. … [L51078]The US FDA subsequently approved insulin icodec in March 2026 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [L56102]